Epidyolex® has gained approval from the European Commission for seizures associated with Lennox–Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
High-grade gliomas may be able to wire themselves into the healthy brain, receiving and interpreting electrical signals from normal neurons.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
A promising new study could provide an early warning system to enable people with epilepsy to know when they are at risk of having a seizure.
A Phase III study has shown that cannabidiol can reduce seizures by almost half in children with Dravet syndrome, a rare type of severe epilepsy.
Zebinix (eslicarbazepine acetate) has received market authorization as a once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy.
Researchers observe clinically silent hippocampal seizures in two Alzheimer’s disease patients during sleep; a period critical for memory consolidation.
Research demonstrates a daily dose of cannabidiol may help reduce seizures in children and adults suffering from Lennox- Gastaut syndrome (LGS).
Authors also claim that stress-reduction techniques could be an effective low-risk treatment for sufferers.
Mark Stewart shares his group’s work on developing an appropriate small animal model for SUDEP, a condition that presents a significant challenge to researchers, particularly given that it occurs rarely and under circumstances where physiological data are seldom available